A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Completed · Phase 3

Conditions studied: Allergic Conjunctivitis

In brief

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

Key facts

Study ID

NCT01881113

Run by

Aciex Therapeutics, Inc.

People needed

101

Starts

2013-06-01

Expected to finish

2013-10-01

Last updated by the study team

2017-11-09

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• positive bilateral conjunctival allergen challenge (CAC) reaction

You may not qualify if…

• known contraindications or sensitivities to the study medication or its components
• any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
• use of disallowed medication during the period indicated prior to the enrollment or during the study

Where it is running

• Ora, Inc. — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.